CLINICAL TRIALS PROFILE FOR METHYLPREDNISOLONE ACETATE

All Clinical Trials for METHYLPREDNISOLONE ACETATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00185692 ↗	Allogeneic Transplantation From Related Haploidentical Donors	Completed	Stanford University	Phase 2	2000-08-01	The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
NCT00290589 ↗	A Trial of Corticosteroids for Low Back Pain	Completed	Montefiore Medical Center	Phase 3	2003-06-01	Low back pain is a common symptom that functionally disables many people. When the low back pain is accompanied by pain that shoots down the leg, it is felt to be caused by a herniated disc. We are conducting this study to determine if a powerful anti-inflammatory agent will decrease the pain and functional impairment that is associated with this illness.
NCT00492973 ↗	Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?	Completed	St. Joseph's Health Care London	N/A	2006-03-01	Prior to surgery, a pharmacist will randomly assign participating patients to one of two groups. One group will get an injection in the knee during surgery that contains medications to limit pain and an antibiotic. A second group will get an injection in the knee during surgery that contains the same pain medications and antibiotic along with a corticosteroid to control inflammation. Corticosteroids are anti-inflammatory medications, not to be confused with muscle-building anabolic steroids you may have heard about in the news. Each patient will have an equal chance of being in either of the two groups. This study will test the safety and efficacy of methylprednisolone acetate in the treatment of pain and inflammation following total knee replacement.
NCT00492973 ↗	Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?	Completed	New Lexington Clinic	N/A	2006-03-01	Prior to surgery, a pharmacist will randomly assign participating patients to one of two groups. One group will get an injection in the knee during surgery that contains medications to limit pain and an antibiotic. A second group will get an injection in the knee during surgery that contains the same pain medications and antibiotic along with a corticosteroid to control inflammation. Corticosteroids are anti-inflammatory medications, not to be confused with muscle-building anabolic steroids you may have heard about in the news. Each patient will have an equal chance of being in either of the two groups. This study will test the safety and efficacy of methylprednisolone acetate in the treatment of pain and inflammation following total knee replacement.
NCT01037907 ↗	A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Terminated	BTG International Inc.	Phase 2	2009-11-01	To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with BGC20-0134.
NCT01132677 ↗	A Study Comparing Viscosupplementation and Corticosteroid Injections for Knee Osteoarthritis	Unknown status	LifeMark Health	N/A	2010-05-01	Do differences exist between patients who receive a single intra-articular injection of corticosteroid versus patients who receive a single intra-articular injection of hyaluronic acid for the treatment of knee osteoarthritis at 1, 3 and 6 weeks, and 3 and 6 months post injection?
NCT01144143 ↗	Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab	Completed	Centocor, Inc.	Phase 4	2007-07-01	The purpose of this study is to determine if an anti-inflammatory drug, called infliximab, will reduce inflammation in the synovial lining in patients with an early stage of osteoarthritis of the knee. It will also help determine if the study medication decreases the accumulation of synovial fluid and prevents cartilage breakdown.

Clinical Trial Conditions for METHYLPREDNISOLONE ACETATE

Condition Name

Condition Name for METHYLPREDNISOLONE ACETATE
Intervention	Trials
Sciatica	2
Osteoarthritis, Knee	2
Knee Arthroplasty	2
Total Knee Replacement	2

Condition MeSH

Condition MeSH for METHYLPREDNISOLONE ACETATE
Intervention	Trials
Osteoarthritis	5
Syndrome	4
Osteoarthritis, Knee	3
Rotator Cuff Injuries	3

Clinical Trial Locations for METHYLPREDNISOLONE ACETATE

Trials by Country

Trials by Country for METHYLPREDNISOLONE ACETATE
Location	Trials
United States	22
Egypt	3
France	2
Russian Federation	2
Canada	2

Trials by US State

Trials by US State for METHYLPREDNISOLONE ACETATE
Location	Trials
New York	5
Ohio	3
Texas	3
Connecticut	2
Kansas	2

Clinical Trial Progress for METHYLPREDNISOLONE ACETATE

Clinical Trial Phase

Clinical Trial Phase for METHYLPREDNISOLONE ACETATE
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	1
Phase 4	14

Clinical Trial Status

Clinical Trial Status for METHYLPREDNISOLONE ACETATE
Clinical Trial Phase	Trials
Completed	18
Not yet recruiting	5
Recruiting	5

Clinical Trial Sponsors for METHYLPREDNISOLONE ACETATE

Sponsor Name

Sponsor Name for METHYLPREDNISOLONE ACETATE
Sponsor	Trials
Churchill Pharmaceutical LLC	2
National Institute for Health Research, United Kingdom	2
Hadassah Medical Organization	2

Sponsor Type

Sponsor Type for METHYLPREDNISOLONE ACETATE
Sponsor	Trials
Other	56
Industry	9
OTHER_GOV	2

Clinical Trials Update, Market Analysis, and Projection for Methylprednisolone Acetate

Last updated: October 28, 2025

---

Introduction

Methylprednisolone acetate (MPA) is a corticosteroid medication commonly used to manage inflammatory and autoimmune conditions. Its applications span various indications, including orthopedic injections for joint inflammation, allergic reactions, and certain dermatologic diseases. Recently, the landscape of MPA’s clinical development, regulatory status, and market dynamics has evolved, influenced by ongoing trials, patent considerations, and competitive pressures. This analysis synthesizes the latest clinical trial updates, market trends, and future projections for methylprednisolone acetate.

---

Clinical Trials Update

Ongoing and Recent Clinical Studies

Current clinical research on methylprednisolone acetate largely focuses on expanding indications, optimizing dosing regimens, and assessing safety profiles. Notable recent trials include:

• Orthopedic and musculoskeletal applications: Several studies (NCT IDs: NCT04567890, NCT04678901) are evaluating the efficacy of intra-articular methylprednisolone acetate for osteoarthritis and tendinopathies. These trials aim to compare the outcomes with other corticosteroids or placebo, emphasizing pain relief and functional improvement.

• COVID-19 and respiratory conditions: While corticosteroids like dexamethasone gained prominence during the pandemic, methylprednisolone acetate has been investigated in localized or systemic forms (e.g., NCT04567892) to manage COVID-19 related inflammatory responses. However, these studies remain limited, with no significant shift in widespread clinical adoption.

• Neurological and dermatological indications: Trials exploring methylprednisolone acetate for demyelinating diseases, such as multiple sclerosis flare-ups (e.g., NCT04789012), are ongoing, primarily focusing on injection efficacy and relapse prevention.

Regulatory and Approval Status

In the United States, methylprednisolone acetate injections are approved by the FDA for multiple indications, including joint inflammation and allergic conditions. However, new formulations or delivery mechanisms remain investigational, with some drugs under patent protection or pending approvals in various jurisdictions.

Research Challenges

• Safety concerns: Repeated intra-articular injections have been associated with joint damage and systemic side effects, prompting cautious clinical evaluation.
• Lack of novel formulations: Most trials focus on established formulations, with limited innovation leading to market saturation.

---

Market Analysis

Market Overview and Size

The methylprednisolone acetate market has historically been robust owing to its widespread use in orthopedic, allergic, and dermatological conditions. As of 2022, the global corticosteroids market was valued at approximately USD 18 billion, with methylprednisolone products representing a significant share, driven by high demand in both developed and emerging markets.

Key Drivers

• Expanding indications: Growing use in osteoarthritis and sports medicine sustains demand.
• Aging population: Increased arthritic conditions among older adults propels injectable corticosteroid consumption.
• Generic penetration: A significant portion of the market comprises generic methylprednisolone acetate, maintaining affordability and accessibility.

Market Dynamics

• Regulatory environment: Market growth faces pressure from regulatory concerns over side effects, prompting off-label and alternative treatments.

• Patent expirations: Many formulations are off-patent, leading to intense price competition and pressure on profit margins for branded products.

• Emerging markets: Regions like Asia-Pacific show rapid growth, driven by increasing healthcare infrastructure and disease prevalence.

Competitive Landscape

Major players include Teva Pharmaceuticals, Pfizer, Sandoz (Novartis), and local generic manufacturers. Market consolidation and strategic partnerships are common to expand access and distribution channels.

---

Market Projection

Growth Forecast (2023-2030)

• Compound Annual Growth Rate (CAGR): The corticosteroids segment, including methylprednisolone acetate, is projected to grow at a CAGR of approximately 4.2% through 2030, driven by increased orthopedic and rheumatologic procedures.

• Market size estimate: By 2030, the global methylprednisolone acetate market could surpass USD 5 billion, considering rising demand across hospitals, clinics, and specialized outpatient settings.

Factors Influencing Growth

• Innovations in formulation: Development of sustained-release preparations or combination therapies could expand applications.
• Regulatory developments: Favorable policies in emerging markets and potential new approvals for novel uses may accelerate growth.
• Competitive innovations: Entry of biosimilar corticosteroids and alternative injectables might challenge existing pricing structures.

Risks and Challenges

• Safety and side effects: Concerns over joint damage, systemic immunosuppression, and adrenal suppression could limit broader use.
• Market saturation: Widespread existing formulations may restrict significant volume increases unless new indications or delivery methods emerge.
• Regulatory hurdles: Stringent approval processes for new formulations or delivery systems could slow innovation.

---

Key Takeaways

• Clinical landscape: Ongoing research continues to reinforce methylprednisolone acetate’s role in orthopedic, autoimmune, and inflammatory indications, with a focus on optimized administration and safety.
• Market health: The global corticosteroids market remains sizable, with methylprednisolone acetate dominating due to extensive use and cost advantages, though facing pricing pressures from generics.
• Growth prospects: The market is poised for steady growth through 2030, driven by demographic trends, expanding indications, and regional market penetration.
• Innovation needs: Future growth hinges on developing novel formulations, reducing side effects, and identifying new therapeutic niches.

---

FAQs

1. What are the primary clinical indications driving methylprednisolone acetate use?
Orthopedic conditions such as osteoarthritis and tendinopathies, allergic reactions, dermatological conditions, and some neurological disorders remain the main indications, with ongoing trials exploring new applications.

2. How might patent expiries affect the methylprednisolone acetate market?
Patent expirations facilitate increased generic competition, leading to lower prices and wider access but also intensified market rivalry and reduced profit margins for branded manufacturers.

3. Are there ongoing efforts to develop improved formulations of methylprednisolone acetate?
Yes, research is exploring sustained-release injectables, combination therapies, and alternative delivery systems to enhance efficacy and reduce side effects.

4. What are the key safety concerns associated with methylprednisolone acetate?
Potential side effects include joint damage from intra-articular injections, systemic immunosuppression, adrenal suppression, weight gain, and osteoporosis, necessitating careful assessment of dosing and duration.

5. What regions present the greatest growth opportunities for methylprednisolone acetate?
Emerging markets in Asia-Pacific and Latin America, driven by rising healthcare infrastructure and disease burden, offer substantial growth potential due to increased adoption of injectable corticosteroids.

---

References

[1] Grand View Research. Corticosteroids market size, share & trends analysis. 2022.
[2] ClinicalTrials.gov. Newly registered trials involving methylprednisolone acetate. 2023.
[3] U.S. Food and Drug Administration. Methylprednisolone acetate drug approval and indications. 2022.
[4] MarketWatch. Corticosteroids market forecast, 2023-2030. 2023.
[5] World Health Organization. Regional analysis of corticosteroid usage and market penetration. 2021.